Please login to the form below

Not currently logged in
Email:
Password:

Helsinn

This page shows the latest Helsinn news and features for those working in and with pharma, biotech and healthcare.

Danish biopharma company wins R&D award

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn

Latest news

  • FDA approves PONV injection

    Developed by Eisai Corporation of North America, its US subsidiary MGI Pharma, and Helsinn Healthcare SA (based in Switzerland), Aloxi has been shown to reduce the severity of PONV. ... Riccardo Braglia, CEO of Helsinn Healthcare SA, said: ìThis is an

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    Late stage licences can also command relatively low upfront fees. For example, Helsinn has licensed pracinostat, which is phase III-ready, for $15m upfront plus $5m equity payment. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Helsinn Therapeutics names Paul Rittman as CEO Helsinn Therapeutics names Paul Rittman as CEO

    Helsinn Therapeutics names Paul Rittman as CEO. He replaces William Mann, who stepped down on 28 February. ... Helsinn, a Swiss pharmaceutical group focused on cancer care products, has appointed Paul Rittman as its new chief executive officer.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics